Foren & Soziale Netzwerke zur PRECIGEN Aktie

 

NASDAQ:PGEN continues to act well from the mid-term support zone highlighted in the September and October updates. I'll be viewing any potential pullbacks toward the rising EMA as possible buying opportunities, with the next target resistance zone near 8. Chart: https://www.tradingview.com/x/xJcOkFZW/ Previously: On support (Oct 8): weekly review — https://www.tradingview.com/chart/BITF/MXF8r9gK-Weekly-Chart-Review-Oct-6-10-2025/ Chart: https://www.tradingview.com/x/vXguxiOJ/ On bullish structure (Sep 15): https://www.tradingview.com/symbols/NASDAQ-PGEN/minds/?mind=Wd5W0WZ3R-qeB9zVjFAHHw Chart: https://www.tradingview.com/x/HbOq5T3D/

The market is overreacting to the NASDAQ:REPL news, and I think it's a mistake to lump NASDAQ:PGEN in with it. Yes, PRGN-2012 is also a single-arm gene therapy trial, but it's for an ultra-rare disease—not a broad indication like cancer. The FDA's tougher stance seems to be focused on common diseases (like NASDAQ:REPL 's melanoma drug), not niche, high-unmet-need therapies like Precigen's. Here's why I'm loading up on this pullback: PRGN-2012 has incredible data: 51% complete response rate, 86% reduction in surgeries (from 4 per year to zero). These patients suffer through painful, repeated procedures—this drug could be life-changing. FDA loves it: Breakthrough Therapy, Orphan Drug, Fast Track, and Priority Review with a PDUFA date of August 27, 2025. If approved, it'll be the first-ever treatment for RRP. Commercial upside: Rare disease drugs have high margins, and there's zero competition. The sell-off is shortsighted. I'm treating this as a fire sale and buying more before the August 2025 catalys